+1.26% for Pfizer stock as buyers keep price above key moving averages

Traders Union
All News
Companies
Pfizer rises 1.26% to $27.30 today

Highlights

Pfizer maintains a bullish trajectory, trading above key moving averages with strong short-, medium-, and long-term technical structure.
Momentum indicators support continued upside with no overbought signals, and intraday buyers remain in control after a 1.26% gain.
The stock is expected to trade between $27.08 and $27.43 in the coming week, with an over 80% probability of further price increases unless support at $27.08 fails.

Pfizer is trading at $27.30, positioning it above the MA-20 ($27.02), MA-50 ($26.73), and MA-200 ($25.35), confirming ongoing bullish momentum in the short, medium, and long-term structure. The Ichimoku Kijun on D1 stands at $26.98, which sits just below the current price and therefore acts as immediate support.

Momentum signals on D1 are constructive, with MACD showing a strong buy and ADX remaining neutral at 15.68, indicating that while the move is upward, trend strength is moderate. Oscillators such as RSI, CCI, and Stoch RSI do not point to overbought or oversold extremes, with RSI at 54.63 and CCI at 77.57, supporting steady upside. BBP at 0.46 registers ongoing buyer dominance for intraday momentum. In today's session, Pfizer is up 1.26% from the previous close, reflecting renewed strength. Over the past week, Pfizer has risen $0.31 (1.17%) from the previous week's close of $26.99. The price is currently in the upper part of the weekly range, while weekly volatility stands at 4.88%. The recent advance is marked by a recovery from the weekly low.

Looking ahead, the expected trading range for the coming week is $27.08–$27.43, keeping the stock near its 52-week high of $27.94 and well above the 52-week low of $20.92. The probability of a price increase is very high (more than 80%), supported by bullish signals from MA-50, RSI, and MACD on W1, while the likelihood of a decline is very low (less than 20%). The baseline scenario envisions continued sideways trading within the projected range. A bullish outcome would see Pfizer breaking above $27.43, targeting fresh yearly highs. A bearish scenario would involve a drop below $27.08, with downside limited by strong near-term supports.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Pfizer showcased new developments from its lung cancer pipeline, highlighting ongoing innovation in oncology. With continued progress in its research initiatives, investors should monitor Pfizer for updates on regulatory milestones that could drive future performance.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.